Hepatitis B Virus Antibody Levels 7 to 9 Years after Booster Vaccination in Alaska Native Persons |
| |
| Authors: | James W Keck Lisa R Bulkow Gregory A Raczniak Susan E Negus Carolyn L Zanis Michael G Bruce Philip R Spradling Eyasu H Teshale Brian J McMahon |
| |
| Institution: | aEpidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA;bArctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA;cLiver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska, USA;dDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA |
| |
| Abstract: | Hepatitis B antibody persistence was assessed in individuals who had previously received a vaccine booster. We measured hepatitis B surface antigen antibody (anti-HBs) levels 7 to 9 years post-hepatitis B booster in individuals with primary vaccination at birth. While 95 (91.3%) of 104 participants had detectable anti-HBs (minimum, 0.1 mIU/ml; maximum, 1,029 mIU/ml), only 43 (41%) had protective levels of ≥10 mIU/ml. Pre- and week 4 postbooster anti-HBs levels were significant predictors of hepatitis B immunity at follow-up (P < 0.001). Almost all participants had detectable anti-HBs 7 to 9 years after the hepatitis B vaccine booster, but less than half had levels ≥10 mIU/ml. |
| |
| Keywords: | |
|
|
